The first joint European Society for Medical Oncology (ESMO), European SocieTy for
Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology …

Endometrial cancer is the most common gynaecological tumour in developed countries, and
its incidence is increasing. The most frequently occurring histological subtype is …

Highlights•This ESMO Clinical Practice Guideline provides key recommendations for
managing endometrial cancer.•The guideline covers clinical and pathological diagnosis …

Endometrial cancer is the most common gynecological malignancy in high‐and middle‐
income countries. Although the overall prognosis is relatively good, high‐grade endometrial …

Purpose: Recommendations for adjuvant treatment for women with early-stage endometrial
carcinoma are based on clinicopathologic features. Comprehensive genomic …

Background PORTEC-2 was a randomised trial for women with high-intermediate risk (HIR)
endometrial cancer, comparing pelvic external beam radiotherapy (EBRT) with vaginal …

Simple Summary The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE)
is a recently developed tool to identify four distinct molecular subgroups of endometrial …

Endometrial cancer is a clinically heterogeneous disease and it is becoming increasingly
clear that this heterogeneity may be a function of the diversity of the underlying molecular …

Endometrial cancer is the most common gynecological malignancy in high‐income
countries. Although the overall prognosis is relatively good, high‐grade endometrial cancers …

Simple Summary Endometrial cancer (EC) is the most common gynaecologic malignancy in
developed countries. Most patients are sufficiently treated with removal of uterus, tubes and …